Literature DB >> 2174958

Purification and characterization of the major group-specific core antigen VP7 of bluetongue virus synthesized by a recombinant baculovirus.

S Oldfield1, A Adachi, T Urakawa, T Hirasawa, P Roy.   

Abstract

The major core protein, VP7, of bluetongue virus serotype 10 (BTV-10) has been purified from insect cells infected with a genetically manipulated recombinant baculovirus. The high level expression of VP7 (in excess of 100 mg per litre of culture) and its presence in the soluble fraction of infected cells following lysis by detergent has allowed the purification of the protein virtually to homogeneity (95%) by a simple two-step procedure of ammonium sulphate fractionation and ion-exchange chromatography. The purified antigen is highly immunogenic and has been shown in an ELISA to be reactive with antisera of 24 BTV serotypes (1 to 24) as well as with an antiserum raised to African horsesickness virus type 4 (AHSV-4), a representative of another serogroup of orbiviruses. In confirmation of these data a monospecific antiserum raised with the expressed product has been shown by Western blot analyses to react with other BTV serotypes as well as with two serotypes of epizootic haemorrhagic disease virus (EHDV-1 and EHDV-2), a closely related orbivirus. The data indicated that VP7 is a highly conserved protein amongst BTV serotypes and at least partly conserved amongst three serogroups of orbiviruses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174958     DOI: 10.1099/0022-1317-71-11-2649

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Intermolecular interactions in a two-layered viral capsid that requires a complex symmetry mismatch.

Authors:  Chang-Kwang Limn; Polly Roy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Bluetongue virus infection alters the impedance of monolayers of bovine endothelial cells as a result of cell death.

Authors:  Clifton P Drew; Ian A Gardner; Christie E Mayo; Eiko Matsuo; Polly Roy; N James MacLachlan
Journal:  Vet Immunol Immunopathol       Date:  2010-03-10       Impact factor: 2.046

3.  Production of a recombinant major inner capsid protein for serological detection of epizootic hemorrhagic disease virus.

Authors:  Lizhong Luo; Marta I Sabara
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

4.  Evaluation of thermo-stability of bluetongue virus recombinant VP7 antigen in indirect ELISA.

Authors:  Gnanavel Venkatesan; Sanchay Kumar Biswas; Veerakyathappa Bhanuprakash; Raj Kumar Singh; Bimelendu Mondal
Journal:  Virusdisease       Date:  2015-02-10

5.  RGD tripeptide of bluetongue virus VP7 protein is responsible for core attachment to Culicoides cells.

Authors:  B H Tan; E Nason; N Staeuber; W Jiang; K Monastryrskaya; P Roy
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Functional dissection of the major structural protein of bluetongue virus: identification of key residues within VP7 essential for capsid assembly.

Authors:  C K Limn; N Staeuber; K Monastyrskaya; P Gouet; P Roy
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Assembly and intracellular localization of the bluetongue virus core protein VP3.

Authors:  Alak Kanti Kar; Nao Iwatani; Polly Roy
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Vaccinia virus expression of the VP7 protein of South African bluetongue virus serotype 4 and its use as an antigen in a capture ELISA.

Authors:  M Cloete; D H du Plessis; A A van Dijk; H Huismans; G J Viljoen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Identification of domains in bluetongue virus VP3 molecules essential for the assembly of virus cores.

Authors:  S Tanaka; P Roy
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Antigen capture competitive enzyme-linked immunosorbent assays using baculovirus-expressed antigens for diagnosis of bluetongue virus and epizootic hemorrhagic disease virus.

Authors:  J O Mecham; W C Wilson
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.